These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36706952)

  • 21. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.
    Facile R; Muhlbradt EE; Gong M; Li Q; Popat V; Pétavy F; Cornet R; Ruan Y; Koide D; Saito TI; Hume S; Rockhold F; Bao W; Dubman S; Jauregui Wurst B
    JMIR Med Inform; 2022 Jan; 10(1):e30363. PubMed ID: 35084343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
    Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
    Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.
    Oehrlein EM; Graff JS; Harris J; Perfetto EM
    Patient; 2019 Aug; 12(4):375-381. PubMed ID: 30666526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
    Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
    Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
    Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
    Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal.
    Pongiglione B; Torbica A; Blommestein H; de Groot S; Ciani O; Walker S; Dams F; Blankart R; Mollenkamp M; Kovács S; Tarricone R; Drummond M
    Int J Technol Assess Health Care; 2021 Apr; 37(1):e62. PubMed ID: 33896433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making.
    Mikl V; Baltic D; Czypionka T; Degelsegger-Márquez A; Forgó N; Gouya-Lechner G; Herzog A; Klimek P; Lumenta DB; Mraz B; Ostermann H; Scharinger R; Stamm T; Strassnig M; Zeitlinger M; Pleiner-Duxneuner J
    Sci Rep; 2024 Apr; 14(1):9751. PubMed ID: 38679653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The application of real-world evidence in drug regulatory decision-making].
    Wicherski J; Haenisch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.
    Facey KM; Rannanheimo P; Batchelor L; Borchardt M; de Cock J
    Int J Technol Assess Health Care; 2020 Sep; ():1-10. PubMed ID: 32878663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
    Deverka PA; Douglas MP; Phillips KA
    Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
    Li P; Wang S; Chen Y
    Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world evidence to support regulatory decision making: New or expanded medical product indications.
    Franklin JM; Liaw KL; Iyasu S; Critchlow CW; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):685-693. PubMed ID: 33675248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics.
    Bloomfield-Clagett B; Rahman M; Smith K; Concato J
    Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.
    Sun F; Bedenkov A; Liu BC; Yang J; Xu JF; Ji L; Zhou M; Zhang S; Li X; Song Y; Chen P; Moreno C
    Pharmaceut Med; 2024 May; 38(3):157-166. PubMed ID: 38573457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.
    Derman BA; Belli AJ; Battiwalla M; Hamadani M; Kansagra A; Lazarus HM; Wang CK
    Blood Rev; 2022 May; 53():100913. PubMed ID: 35272867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.